Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice

Key Points

• This research investigates how SSR504734 interacts with various antiseizure medications to enhance their effects and assesses potential safety concerns.
• Conducted pharmacodynamic and pharmacokinetic studies in mice.
• Assessed serum and brain concentrations of SSR504734 and antiseizure drugs.
• Evaluated the effects of SSR504734 alone and in combination with other drugs.
• SSR504734 improved the antiseizure effect of all drugs except ethosuximide.
• Documented changes in serum and brain levels of both SSR504734 and the tested antiseizure drugs.
• High doses of SSR504734, either alone or with antiseizure drugs, led to adverse effects.